Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript
11:36pm, Thursday, 30'th Oct 2025
Invivyd, Inc. ( IVVD ) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention October 30, 2025 8:30 AM EDT Company Participants Katie Falzone Marc Elia Robert A
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
07:01am, Tuesday, 28'th Oct 2025
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical prog
NEW HAVEN, Conn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IN
Invivyd Appoints Paul B. Bolno, M.D.
04:01pm, Wednesday, 24'th Sep 2025
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
07:01am, Wednesday, 17'th Sep 2025
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's comm
WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design to eval
Invivyd to Participate in Upcoming Investor Conferences
07:01am, Wednesday, 27'th Aug 2025
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences: Cantor Global Healthcare Conference 2025 Fire
This Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?
10:09am, Tuesday, 26'th Aug 2025
Invivyd (NASDAQ: IVVD), a biopharmaceutical company focused on developing protection against serious viral infectious diseases, is back in the spotlight with notable share price movement.
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of it
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
11:58pm, Wednesday, 20'th Aug 2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an o
Invivyd Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 20'th Aug 2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In additio
WALTHAM, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA® (pemivibart) again
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
07:01pm, Thursday, 14'th Aug 2025
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago.
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
04:49pm, Thursday, 14'th Aug 2025
WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided recent business highlights.
Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary en
